Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as an attractive investment opportunity by hedge funds due to its low valuation [1] - Positive interim data from a Phase 2 trial of the bispecific antibody pumitamig (BNT327/BMS986545) in combination with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) was presented [1][2] - The trial demonstrated encouraging anti-tumor activity and a manageable safety profile, with a discontinuation rate of 14% [2] Company Overview - Bristol-Myers Squibb is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products globally [4] - BioNTech focuses on developing and commercializing immunotherapies for cancer and infectious diseases, primarily in Germany [4] Trial Details - The Phase 2 trial included 43 patients with previously untreated ES-SCLC and showed results consistent with a prior trial conducted in China [2] - Pumitamig operates through dual mechanisms: PD-L1 checkpoint inhibition and neutralization of VEGF-A, aimed at enhancing the immune response against cancer and depriving tumors of blood supply [3] - The positive results support the ongoing global pivotal Phase 3 trial, ROSETTA LUNG-01, which compares pumitamig plus chemotherapy against standard-of-care treatment [3] - Pumitamig received Orphan Drug designation from the US FDA for small-cell lung cancer treatment in 2025 [3]